TY - JOUR
T1 - Critical Roles of EGFR family members in breast cancer and breast cancer stem cells
T2 - Targets for therapy
AU - Steelman, Linda S.
AU - Fitzgerald, Timothy
AU - Lertpiriyapong, Kvin
AU - Cocco, Lucio
AU - Follo, Matilde Y.
AU - Martelli, Alberto M.
AU - Neri, Luca M.
AU - Marmiroli, Sandra
AU - Libra, Massimo
AU - Candido, Saverio
AU - Nicoletti, Ferdinando
AU - Scalisi, Aurora
AU - Fenga, Concettina
AU - Drobot, Lyudmyla
AU - Rakus, Dariusz
AU - Gizak, Agnieszka
AU - Laidler, Piotr
AU - Dulińska-Litewka, Joanna
AU - Basecke, Joerg
AU - Mijatovic, Sanja
AU - Maksimovic-Ivanic, Danijela
AU - Montalto, Giuseppe
AU - Cervello, Melchiorre
AU - Milella, Michelle
AU - Tafuri, Agustino
AU - Demidenko, Zoya
AU - Abrams, Stephen L.
AU - McCubrey, James A.
PY - 2016/5/1
Y1 - 2016/5/1
N2 - The roles of the epidermal growth factor receptor (EGFR) signaling pathway in various cancers including breast, bladder, brain, colorectal, esophageal, gastric, head and neck, hepatocellular, lung, neuroblastoma, ovarian, pancreatic, prostate, renal and other cancers have been keenly investigated since the 1980’s. While the receptors and many downstream signaling molecules have been identified and characterized, there is still much to learn about this pathway and how its deregulation can lead to cancer and how it may be differentially regulated in various cell types. Multiple inhibitors to EGFR family members have been developed and many are in clinical use. Current research often focuses on their roles and other associated pathways in cancer stem cells (CSCs), identifying sites where therapeutic resistance may develop and the mechanisms by which microRNAs (miRs) and other RNAs regulate this pathway. This review will focus on recent advances in these fields with a specific focus on breast cancer and breast CSCs. Relatively novel areas of investigation, such as treatments for other diseases (e.g., diabetes, metabolism, and intestinal parasites), have provided new information about therapeutic resistance and CSCs.
AB - The roles of the epidermal growth factor receptor (EGFR) signaling pathway in various cancers including breast, bladder, brain, colorectal, esophageal, gastric, head and neck, hepatocellular, lung, neuroblastoma, ovarian, pancreatic, prostate, renal and other cancers have been keenly investigated since the 1980’s. While the receptors and many downstream signaling molecules have been identified and characterized, there is still much to learn about this pathway and how its deregulation can lead to cancer and how it may be differentially regulated in various cell types. Multiple inhibitors to EGFR family members have been developed and many are in clinical use. Current research often focuses on their roles and other associated pathways in cancer stem cells (CSCs), identifying sites where therapeutic resistance may develop and the mechanisms by which microRNAs (miRs) and other RNAs regulate this pathway. This review will focus on recent advances in these fields with a specific focus on breast cancer and breast CSCs. Relatively novel areas of investigation, such as treatments for other diseases (e.g., diabetes, metabolism, and intestinal parasites), have provided new information about therapeutic resistance and CSCs.
KW - Cancer Stem Cells
KW - Drug Resistance
KW - EGFR
KW - HER2
KW - Metastasis
KW - mIRs
UR - http://www.scopus.com/inward/record.url?scp=84974712888&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84974712888&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:84974712888
VL - 22
SP - 2358
EP - 2388
JO - Current Pharmaceutical Design
JF - Current Pharmaceutical Design
SN - 1381-6128
IS - 16
ER -